Tongshu Gene Completes Series D Financing to Propel Precision Oncology into a New Era

VCBeat learned that on October 8, 2024, Wuxi Tongshu Biotechnology Co., Ltd. (hereinafter referred to as “Tongshu Gene”) officially completed its Series D financing of over RMB 100 million. This round of financing was led byWuxi Liangxi Sci-Tech Innovation Industry Investment Fund (Bohua Capital Management)Lead investor,Jiangsu Jiandao Venture Capital Co., Ltd.Co-investment.

The success of this Series D financing round not only reflects investors’ strong recognition and confidence in TONGSHU GENE, but also highlights the company’s significant potential in the field of genetic testing. The funds will be primarily used to continuously strengthen R&D investment, expand production capacity, broaden market channels, and enhance brand influence.

TONGSHU GENE has been deeply engaged in the field of genetic testing for seven years, adhering to a “product + service” strategy centered on hospitals. By addressing clinical needs, the company has developed a series of IVD diagnostic technologies with significant technical barriers. In the realm of IVD product development, TONGSHU GENE possesses comprehensive and complete technical platforms, offering extensive and in-depth technological coverage.

Leveraging core innovative technologies across multiple platforms, we have developed IVD products with distinct technical advantages in the fields of first-generation sequencing, next-generation sequencing (NGS), quantitative real-time PCR (qPCR), and CRISPR.

TONGSHU GENE’s independently developed microsatellite instability (MSI) detection kit received China’s first Class III medical device registration certificate for MSI testing in January 2021, securing a first-mover advantage in the detection of 17 types of tumors, including gastric cancer, colorectal cancer, and breast cancer.

In March 2024, TONGSHU GENE successfully launched its pan-site osimertinib companion diagnostic kit, filling a domestic gap. This kit employs a non-ARMS-PCR method leveraging proprietary MASS technology to accurately identify EGFR gene mutations, providing a reliable basis for precision treatment of lung cancer.

TONGSHU GENE is rooted in the Chinese market and has actively expanded its sales channels, with its genetic testing services now covering more than 1,000 hospitals across over 30 provinces, municipalities, and autonomous regions in China. After years of collaboration and refinement, TONGSHU GENE’s sales team has achieved industry-leading sales capabilities. Over the seven years since its establishment, the company has realized rapid growth in sales revenue and has firmly secured its position among the top tier of the industry. As more blockbuster products obtain regulatory approvals one by one, TONGSHU GENE is poised to become a leader in the trillion-yuan precision oncology market.

TONGSHU GENE’s products and services provide clinicians with more accurate diagnostic evidence, help formulate personalized treatment plans for patients, and improve therapeutic outcomes. Committed to social responsibility, TONGSHU GENE actively participates in public welfare initiatives and promotes the application of tumor genetic testing technologies. Upholding its philosophy of “Innovation • Creating Value for Cancer Patients,” TONGSHU GENE will continue to contribute to human health and the building of a healthier society.

Powered by New Quality Productive Forces as a Strong Engine, Technological Innovation Leads Life Sciences: TONGSHU GENE Propels Cancer Treatment into a New Era of Precision Medicine.